GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (FRA:RPD) » Definitions » 12-1 Month Momentum %

Royalty Pharma (FRA:RPD) 12-1 Month Momentum % : -15.46% (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-05), Royalty Pharma's 12-1 Month Momentum % is -15.46%.

The industry rank for Royalty Pharma's 12-1 Month Momentum % or its related term are showing as below:

FRA:RPD's 12-1 Month Momentum % is ranked better than
52.09% of 1482 companies
in the Biotechnology industry
Industry Median: -21.305 vs FRA:RPD: -15.46

Competitive Comparison of Royalty Pharma's 12-1 Month Momentum %

For the Biotechnology subindustry, Royalty Pharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's 12-1 Month Momentum % falls into.



Royalty Pharma  (FRA:RPD) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Royalty Pharma  (FRA:RPD) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Royalty Pharma 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Royalty Pharma (FRA:RPD) Business Description

Traded in Other Exchanges
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.